Myrbetriq is expected to go generic in the United States in 2027 [1][2]. This timing is based on the patent expiry dates for the drug's active ingredient, mirabegron [1][3].
What is Myrbetriq?
Myrbetriq is a medication used to treat overactive bladder (OAB) with symptoms of urge urinary incontinence, urinary urgency, and urinary frequency [1]. Its active ingredient is mirabegron, which works by relaxing the detrusor muscle in the bladder, increasing bladder capacity [1].
What is the patent status of Myrbetriq?
The primary patents covering Myrbetriq and its active ingredient, mirabegron, are set to expire around 2027 [1][3]. DrugPatentWatch.com indicates that the key patents for mirabegron expire in 2027, which typically allows for generic versions of the drug to enter the market [1].
Can generic Myrbetriq be available before patent expiry?
While patent expiry is the primary driver for generic drug availability, legal challenges and settlements can sometimes alter these timelines. However, without specific information on any ongoing patent litigation for Myrbetriq, the expected generic entry remains aligned with the patent expiry dates [1][3].
How does generic Myrbetriq affect pricing?
The introduction of generic versions of a medication typically leads to a significant decrease in price [2]. This is due to increased competition among manufacturers. Patients and healthcare systems often see cost savings once generic alternatives become available.
Who manufactures Myrbetriq?
Myrbetriq is manufactured by Astellas Pharma [1]. Once patents expire, other pharmaceutical companies will be able to produce and market generic versions of mirabegron.
What is the timeline for generic mirabegron?
Based on current patent information, generic mirabegron is anticipated to become available in the U.S. in 2027 [1][3].
What are the alternatives to Myrbetriq for overactive bladder?
Other treatment options for overactive bladder include behavioral therapies, other prescription medications with different mechanisms of action, and in some cases, medical procedures [4]. Medications include anticholinergics, which work by blocking nerve impulses to the bladder muscle [4].
What clinical data supports Myrbetriq?
Clinical trials have demonstrated that mirabegron is effective in reducing OAB symptoms, such as urinary urgency, frequency, and incontinence episodes [1]. These studies have been instrumental in its approval by regulatory agencies like the U.S. Food and Drug Administration (FDA).
What are patient concerns about overactive bladder treatment?
Patients often express concerns regarding medication side effects, effectiveness, and the cost of treatment for OAB [4]. For treatments like Myrbetriq, potential side effects include elevated blood pressure, urinary tract infections, and constipation [1]. The availability of generics can alleviate cost concerns for patients.
Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/drug/mirabegron
[3] https://www.drugpatentwatch.com/patent/mirabegron
[4] https://www.mayoclinic.org/diseases-conditions/overactive-bladder/diagnosis-treatment/drc-20351473